Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.44 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961862 | 0.93 | PTGDR2 (0.48) | PTGDR2OXER1KDM4EKMOMAPK8 | |
| SCHEMBL963803 | 0.92 | MAPK8 (0.39) | PTGDR2OXER1RAB9ANPC1KMT2A | |
| SCHEMBL963701 | 0.84 | PTGDR2 (0.37) | PTGDR2OXER1KMORAB9ANPC1 | |
| SCHEMBL963703 | 0.84 | PTGDR2 (0.37) | PTGDR2OXER1KMORAB9ANPC1 | |
| SCHEMBL968306 | 0.83 | OXER1 (0.45) | PTGDR2OXER1KMORAB9ANPC1 | |
| SCHEMBL963044 | 0.82 | OXER1 (0.49) | PTGDR2OXER1KMOMAPK8 | |
| SCHEMBL963809 | 0.82 | MAPK8 (0.36) | PTGDR2OXER1KMORAB9ANPC1 | |
| SCHEMBL963435 | 0.81 | MAPK8 (0.38) | PTGDR2OXER1RAB9ANPC1KMT2A | |
| SCHEMBL964505 | 0.80 | PTGDR2 (0.39) | PTGDR2OXER1KDM4EKMOKMT2A | |
| SCHEMBL961662 | 0.80 | KMT2A (0.41) | PTGDR2OXER1KMORAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | PTGDR2 2740/4885OXER1 2529/4885KDM4E 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.